Forty Seven, Inc. Announces Proof-of-Concept Data from Two Clinical Trials of 5F9 In Patients with Advanced Solid Tumors and Non-Hodgkin’s Lymphoma

Forty Seven, Inc. Announces Proof-of-Concept Data from Two Clinical Trials of 5F9 In Patients with Advanced Solid Tumors and Non-Hodgkin’s Lymphoma

June 3, 2018 — 5F9 Safe and Well-Tolerated Using Proprietary Priming and Maintenance Dosing Strategy — — Objective Response Rate of 50 Percent and Complete Response Rate of 36 Percent Reported in Patients with Relapsed/Refractory non-Hodgkin’s Lymphoma in Combination with